Jin Medical Shareholders Greenlight Sweeping Governance Overhaul and $105M Acquisition
ZJYL sits 16% above its 52-week low of $1.641.
Summary
At the July 20 meeting, Jin Medical shareholders approved all proposals, including a 27x increase in Class B voting rights, a massive share authorization increase, a share swap with the CEO, and the $105 million Tongsheng acquisition.
Key Events · M&A and Partnerships · ZJYL
-
Class B Voting Rights Surge to 800/Share
Effective immediately, Class B voting rights were increased from 30 to 800 votes per share. With CEO Wang Erqi controlling all 1,000,000 Class B shares, he now commands 800 million votes against just 6.8 million Class A votes — giving him near-total voting control.
-
Authorized Shares Skyrocket to 15 Billion
The authorized Class A share count was raised from 45 million to 15 billion, creating enormous dilution headroom. At the current $1.90 price, this represents potential future issuance capacity far exceeding the company's $15.7M market cap.
-
CEO Share Swap: Repurchase and Reissuance
Under the approved plan, the company will repurchase 3,769,057 Class A shares from CEO Wang Erqi at the 90-day low VWAP, then immediately issue him 3,769,057 new Class B shares at the 90-day VWAP. This consolidates his voting power while reducing the Class A float.
-
$105M Tongsheng Acquisition Approved
The acquisition of Beijing Tongsheng Technology via issuance of 64,186,456 Class A shares at $1.641 per share was approved. This represents massive dilution — the new shares are roughly 9.4x the current 6.8M Class A shares outstanding.
Analysis · ZJYL · Industrial Applications And Services
In a decisive vote, shareholders overwhelmingly approved a package that dramatically consolidates CEO Wang Erqi's control while clearing the path for a major acquisition. The Class B voting rights jump from 30 to 800 votes per share, handing Wang near-total voting power. At the same time, the company will repurchase 3.77 million Class A shares from Wang and issue him an equal number of new Class B shares, further entrenching his grip. The authorized Class A share count balloons from 45 million to 15 billion, creating massive dilution headroom. Also approved was the acquisition of Tongsheng for 64.2 million shares at $1.641 each — a deal valued at roughly $105 million. First proposed on June 29, these moves are now fully authorized, marking a fundamental shift in corporate governance and capital structure.
At the time of this filing, ZJYL was trading at $1.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $15.7M. The 52-week trading range was $1.64 to $17.18. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.